Survey says most want disclosure of gifts to docs

Share this article:

Sixty-eight percent of Americans surveyed said they are “very likely” or “somewhat likely” to support legislation requiring pharma companies to disclose gifts to doctors.

The telephone survey was conducted for Community Catalyst's Prescription Project by International Communications Research. Between June 4 and June 8, a total of 1,009 adults aged 18 and older responded, according to the study. The survey asked participants to respond to questions via Likert scale in an attempt to gage the public consensus on corporate gifts to physicians.

The findings suggest that 64% of the survey participants consider the “importance of knowing physician's financial ties to pharma companies” to be “very important (33%)” or “somewhat important (31%).” However, 55% of those surveyed reported it “somewhat unlikely (13%)” or “very unlikely (42%)” that they would ask a doctor directly about his or her relationship with pharma companies, according to the data.

When asked which types of gifts should not be allowed, 86% of respondents said travel expenses, while 51% said free drug samples should not be allowed. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...